CVS Health Corporation (NYSE:CVS)‘s stock had its “buy” rating reiterated by analysts at Credit Suisse Group AG in a report released on Tuesday. They presently have a $115.00 target price on the pharmacy operator’s stock. Credit Suisse Group AG’s target price would suggest a potential upside of 27.79% from the company’s current price.

Several other research analysts have also issued reports on CVS. Leerink Swann restated a “buy” rating on shares of CVS Health Corporation in a research report on Friday, June 10th. FBR & Co restated an “outperform” rating and issued a $120.00 price target on shares of CVS Health Corporation in a research report on Wednesday, August 3rd. Zacks Investment Research upgraded shares of CVS Health Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, August 3rd. Morgan Stanley restated a “hold” rating and issued a $104.00 price target on shares of CVS Health Corporation in a research report on Wednesday, August 3rd. Finally, Argus restated a “buy” rating and issued a $120.00 price target on shares of CVS Health Corporation in a research report on Thursday, August 4th. Six research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $113.02.

Analyst Recommendations for CVS Health Corporation (NYSE:CVS)

Shares of CVS Health Corporation (NYSE:CVS) traded up 0.92% during mid-day trading on Tuesday, reaching $89.99. The company had a trading volume of 5,464,965 shares. CVS Health Corporation has a 52-week low of $86.50 and a 52-week high of $106.67. The stock has a market capitalization of $95.95 billion, a P/E ratio of 20.70 and a beta of 0.84. The company’s 50-day moving average is $94.74 and its 200 day moving average is $98.04.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/cvs-health-corporation-cvs-stock-rating-reaffirmed-by-credit-suisse-group-ag.html

CVS Health Corporation (NYSE:CVS) last posted its quarterly earnings results on Tuesday, August 2nd. The pharmacy operator reported $1.32 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.30 by $0.02. The firm had revenue of $43.70 billion for the quarter, compared to analyst estimates of $44.28 billion. CVS Health Corporation had a net margin of 2.88% and a return on equity of 15.86%. The firm’s quarterly revenue was up 17.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.19 earnings per share. Analysts anticipate that CVS Health Corporation will post $5.86 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CVS. State Street Corp raised its position in CVS Health Corporation by 2.4% in the first quarter. State Street Corp now owns 44,552,112 shares of the pharmacy operator’s stock worth $4,621,391,000 after buying an additional 1,023,799 shares in the last quarter. Nordea Investment Management AB increased its position in CVS Health Corporation by 61.3% in the second quarter. Nordea Investment Management AB now owns 11,644,431 shares of the pharmacy operator’s stock valued at $1,114,838,000 after buying an additional 4,423,216 shares during the last quarter. Magellan Asset Management Ltd increased its position in CVS Health Corporation by 1.6% in the second quarter. Magellan Asset Management Ltd now owns 10,300,505 shares of the pharmacy operator’s stock valued at $986,170,000 after buying an additional 160,188 shares during the last quarter. Dimensional Fund Advisors LP increased its position in CVS Health Corporation by 2.3% in the second quarter. Dimensional Fund Advisors LP now owns 9,278,646 shares of the pharmacy operator’s stock valued at $888,270,000 after buying an additional 205,585 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in CVS Health Corporation by 0.9% in the first quarter. Geode Capital Management LLC now owns 8,917,040 shares of the pharmacy operator’s stock valued at $923,085,000 after buying an additional 77,690 shares during the last quarter. 81.08% of the stock is owned by hedge funds and other institutional investors.

About CVS Health Corporation

CVS Health Corporation, together with its subsidiaries, is a pharmacy company. The Company operates through three business segments: Pharmacy Services, Retail Pharmacy and Corporate. The Pharmacy Services segment provides a range of pharmacy benefit management (PBM) services and operates under the CVS/caremark Pharmacy Services, Novologix and Navarro Health Services names.

5 Day Chart for NYSE:CVS

Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.